MedPath

SHANDONG LUKANG PHARMACEUTICAL CO.LTD.

🇨🇳China
Ownership
-
Established
1993-02-15
Employees
3.3K
Market Cap
-
Website
www.lkpc.com
Introduction

The company is a state-owned comprehensive pharmaceutical enterprise. It was founded in 1966 and listed on the main board of the Shanghai Stock Exchange in 1997. In 2006, Lukang Pharmaceutical was owned by Hualu Holding Group Co., Ltd. Hualu Group was incorporated in Hong Kong in 1985. It focuses on the three major businesses of high-end chemicals, biomedicine, and ecological protection, and actually controls 3 listed companies, 4 stocks, and 5 unlisted companies including the Provincial Academy of Environmental Sciences and Hong Kong Hualu. It owns 63 enterprises, employs 0.018 million people, and has total assets of 51 billion yuan. The company is mainly engaged in R&D, production and sales of pharmaceutical products. The company's products include antibiotics, amino acids, cardiovascular, antiviral, digestive, endocrine, respiratory, semi-synthetic antibiotic raw materials, biopharmaceuticals, and related preparations, infusions, proprietary Chinese medicines, pharmaceutical intermediates, antibiotics for animal health, starch, glucose, etc. The products cover more than 500 product standards such as capsules, tablets, dispersible tablets, powder injections, granules, dry suspensions, water injections, premixes, compound preparations, etc. Corporate honors: National High-tech Enterprise; Premium Credit Enterprise; National Enterprise Technology Center; AAA Credit Enterprise with Enterprise Credit Evaluation, China's Top 100 Pharmaceutical Industry Enterprises, High-end Brands in Shandong Manufacturing Industry, Advanced Energy Saving and Consumption Reduction Enterprise, etc., which have won honorary titles such as National Advanced Quality and Efficiency Enterprise and Model Enterprise for Pharmaceutical Quality and Integrity Construction.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

192

NMPA:192

Drug Approvals

Levamlodipine Besilate Tablets

Product Name
苯磺酸左氨氯地平片
Approval Number
国药准字H20254166
Approval Date
May 13, 2025
NMPA

Levamlodipine Besilate Tablets

Product Name
苯磺酸左氨氯地平片
Approval Number
国药准字H20254165
Approval Date
May 13, 2025
NMPA

Ezetimibe Tablets

Product Name
依折麦布片
Approval Number
国药准字H20253162
Approval Date
Jan 14, 2025
NMPA

Apixaban Tablets

Product Name
阿哌沙班片
Approval Number
国药准字H20249321
Approval Date
Nov 15, 2024
NMPA

Amoxicilin Capsules

Product Name
阿莫西林胶囊
Approval Number
国药准字H20247256
Approval Date
Oct 29, 2024
NMPA

Febuxostat Tablets

Product Name
非布司他片
Approval Number
国药准字H20249007
Approval Date
Sep 26, 2024
NMPA

Febuxostat Tablets

Product Name
非布司他片
Approval Number
国药准字H20249008
Approval Date
Sep 26, 2024
NMPA

Vancomycin Hydrochloride for Injection

Product Name
注射用盐酸万古霉素
Approval Number
国药准字H20244955
Approval Date
Sep 19, 2024
NMPA

Moxifloxacin Hydrochloride Tablets

Product Name
盐酸莫西沙星片
Approval Number
国药准字H20244634
Approval Date
Aug 5, 2024
NMPA

Cefadroxil Capsules

Product Name
头孢羟氨苄胶囊
Approval Number
国药准字H20247095
Approval Date
May 8, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 20
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.